VIRAL INFECTION GROUP / CARE & TRANSMISSION
Human papillomaviruses
HPV is a large family of very common viruses. Most infections clear without treatment. A few high-risk types can, if they persist for years, lead to cancer, and other types cause warts. Vaccination and regular screening protect more than trying to prove anyone is "HPV-negative". [38][39]
Transmission risk
Risk by type of contact
Bottom line. HPV transmission depends on type and contact site, and condoms provide partial protection rather than full skin coverage. Vaccination prevents important vaccine-type outcomes; a single universal per-act HPV percentage is not supported.
General
Oral
Vaginal
Anal
Kissing
What changes the risk (3)
- Vaccination. MEDIUM for a particular trial endpoint: nine-valent vaccine efficacy against high-grade disease due to the five additional vaccine types was 97.4% (95% CI 85.0-99.9) in susceptible per-protocol women versus quadrivalent vaccine. This is not 97.4% protection against every HPV infection, route or act. Sources 6
- Circumcision. MEDIUM: a Ugandan randomized trial found adjusted high-risk penile HPV prevalence ratio 0.65 (95% CI 0.46-0.90). This is a prevalence/site-sampling endpoint, not a per-act acquisition effect or oral/anal protection. Sources 7
- Outcome measurement. MEDIUM: HPV type, sampling site, clearance, possible deposition and reactivation affect apparent acquisition. Incidence densities are not annual probabilities. Sources 2
Condoms and dental dams
Winer prospective cohort: adjusted HR 0.30 (95% CI 0.10-0.60); HITCH Bayesian cohort reanalysis: rate ratio 0.22 (posterior interval 0.05-0.61). Different measures, neither an oral/anal/dam efficacy estimate or complete protection. Evidence: Medium Sources 3, 2
Sources for this risk profile (7)
- CDC CDC, 2021. Human Papillomavirus (HPV) Infection - STI Treatment Guidelines. cdc.gov
- Malagon T et al. Epidemiology, 2021. Sex- and type-specific genital human papillomavirus transmission rates between heterosexual partners: a Bayesian reanalysis of the HITCH cohort. DOI: 10.1097/EDE.0000000000001324. pmc.ncbi.nlm.nih.gov
- Winer RL et al. New England Journal of Medicine, 2006. Condom use and the risk of genital human papillomavirus infection in young women. DOI: 10.1056/NEJMoa053284. nejm.org
- CDC CDC, 2024. About STI Risk and Oral Sex. cdc.gov
- Burchell AN et al. American Journal of Epidemiology, 2006. Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. DOI: 10.1093/aje/kwj077. pubmed.ncbi.nlm.nih.gov
- Huh WK et al. Lancet, 2017. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. DOI: 10.1016/S0140-6736(17)31821-4. pubmed.ncbi.nlm.nih.gov
- Tobian AAR et al. New England Journal of Medicine, 2009. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. DOI: 10.1056/NEJMoa0802556. pubmed.ncbi.nlm.nih.gov
* How to read these figures. Each is a published estimate under the conditions shown beside it, usually an untreated partner and a single act or partnership. It is not a prediction of your personal risk.
- Evidence: High
- Several prospective studies or a systematic review broadly agree.
- Evidence: Medium
- One or two studies, wide uncertainty, or a model.
- Evidence: Low
- Guideline judgment, case reports, or extrapolation.
Where no risk level is shown, the evidence cannot rank it. That is not the same as low.
Evidence reviewed through 2026-10-27. For reference only; not medical advice.
When to test after a possible exposure
No routine exposure-based test window can establish a person's complete HPV status.
When to be seen sooner. Unusual growths or symptoms that persist are worth having checked, without waiting for a presumed window.
-
HPV testing within approved cervical or selected specialist screening pathways
Do not create a days-after-sex or days-after-kissing clearance date.
Follow the applicable screening program rather than an exposure countdown; assess visible lesions or concerning symptoms.
Specimens: Cervical or approved vaginal self-collection specimen, depending on the specific test/program; specialist sites only when indicated
Sources 1, 2
Early negatives, after treatment, and screening limits
An early negative result. A negative site-specific screen does not exclude HPV elsewhere or establish freedom from every type.
After treatment. Follow-up after abnormal screening or treatment is a separate risk-based pathway, not a universal post-exposure test-of-cure schedule.
Screening limits. No test provides a complete whole-body HPV status; no approved routine oral/throat HPV screening test is described by CDC. A screening result cannot reliably date infection.
Kissing and body sites. No routine HPV test window exists after kissing. Oral symptoms are assessed clinically rather than by an all-clear HPV panel.
Sources for testing guidance (2)
- CDC. About Genital HPV Infection: testing limitations. 2025. cdc.gov
- Wentzensen N et al., Journal of Lower Genital Tract Disease. Self-Collected Vaginal Specimens for HPV Testing: Enduring Consensus recommendations. 2025. DOI: 10.1097/LGT.0000000000000885. pmc.ncbi.nlm.nih.gov
Treatment
There is no medication that eradicates all HPV infection. Clinicians treat warts, precancerous lesions or cancer as appropriate. Vaccines prevent new infections with covered types; they do not treat an infection already present. Continue indicated cervical screening after vaccination. [38][39][70]
Actions
1. Check vaccination. Review the schedule and eligibility in the relevant country. US recommendations include routine vaccination and catch-up through age 26; ages 27-45 may involve shared decision-making. Previous exposure does not mean every covered type has been encountered. [70]
2. Screen the right tissue. Follow cervical screening guidance when a cervix is present; additional screening depends on clinical risk and local policy. No blood, urine or throat test establishes complete HPV status across all sites. [38][39]
3. Talk about results without backdating. There is no standard partner lookback, and no routine treatment for a partner without symptoms. A new HPV result can reflect an old infection or reactivation. New growths or abnormal screening results are followed up as usual. [38]
SCIENCE & CONTEXT
HPV / the evidence
History
Research in the early 1980s identified HPV DNA in cervical cancers, advancing understanding of viral carcinogenesis. The first prophylactic HPV vaccine was licensed in the US in 2006, followed by broader-type coverage. Vaccination and screening address different points in the disease pathway and are complementary. [39]
Impact
Most infections clear or become undetectable within one to two years. Low-risk types can cause genital warts. High-risk types that persist can, over years, lead to precancerous changes and cancers of the cervix, anus, penis, vulva, vagina or back of the throat; a positive high-risk test is not a cancer diagnosis, and screening finds changes early. [38][39]
A historical US survey found any genital HPV DNA in 42.5% of adults ages 18-59 and high-risk types in 22.7%. Those 2013-2014 data predate further vaccine uptake and are not a current universal prevalence estimate. Detectable genital DNA is also not the same as lifetime exposure or oral infection. [40]
Probability at a glance
Chance that at least one recent partner has genital HPV, by number of partners in six months, using historical US figures. Most HPV clears on its own.
| Partners | Any HPV: 42.5% | High-risk: 22.7% |
|---|---|---|
1-2 | 42.5–66.9 | 22.7–40.2 |
3-5 | 81.0–93.7 | 53.8–72.4 |
6-10 | 96.4–99.6 | 78.7–92.4 |
11-20 | 99.8–>99.9 | 94.1–99.4 |
Historical genital-DNA scenarios; the two columns overlap because high-risk types are a subset of any HPV. They must not be added together. Neither column predicts cancer or acquisition in a vaccinated person. [40]
In short: HPV is part of most sexually active lives. Vaccination and screening are what make the difference, and a positive test is usually something the body clears.